Tegavivint for the Treatment of Solid Tumors, Lymphomas & Desmoids
Contact
Description
This study has two parts. Part A enrolls patients who have been diagnosed with a solid tumor, lymphoma or desmoid tumor that has either come back ("relapsed") or does not respond to therapy ("is refractory"). Part B enrolls patients with a relapsed or refractory Ewing sarcoma, desmoid tumor, osteosarcoma, liver tumor, Wilms tumor, or tumors with changes in a gene family known as the Wnt pathway. This study involves taking a study drug called tegavivint. The study will be testing different doses of the study drug to find the safest dose.
Eligibility and criteria
IRB Number:
21-019434
Eligible age range:
Clinical trial phase:
Phase I
Phase II
Official title:
What to expect
- Receive a study drug called tegavivint
- Complete frequent clinic visits at CHOP
- Have frequent blood tests
- Have DEXA scans to measure your bone density
- Have knee x-rays if under the age of 18
- Have extra or leftover tissue collected if they have a biopsy as part of regular cancer care
- Have periodic electrocardiograms (ECGs)
Related specialties
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.